Neublastin

Drug Profile

Neublastin

Alternative Names: Artemin; ARTN; BG-00010; Enovin

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NsGene
  • Developer Biogen; NsGene
  • Class Nerve growth factors; Proteins
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuropathic pain; Radiculopathy; Sciatica

Most Recent Events

  • 07 Aug 2015 Discontinued - Phase-I for Sciatica in Australia (SC)
  • 27 Jul 2015 Discontinued - Phase-I for Neuropathic pain in Denmark (IV)
  • 27 Jul 2015 Discontinued - Phase-I for Radiculopathy in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top